Zoetis Inc. (NYSE:ZTS) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 11.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,252 shares of the company's stock after selling 8,034 shares during the quarter. Segall Bryant & Hamill LLC's holdings in Zoetis were worth $10,250,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Navigoe LLC purchased a new stake in shares of Zoetis during the fourth quarter valued at approximately $30,000. Cornerstone Planning Group LLC increased its position in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after buying an additional 88 shares in the last quarter. Murphy & Mullick Capital Management Corp acquired a new position in shares of Zoetis in the fourth quarter valued at about $44,000. Sound Income Strategies LLC boosted its position in Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after purchasing an additional 164 shares in the last quarter. Finally, Bfsg LLC increased its holdings in shares of Zoetis by 614.6% in the first quarter. Bfsg LLC now owns 293 shares of the company's stock valued at $48,000 after purchasing an additional 252 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is currently owned by company insiders.

Zoetis Stock Performance

ZTS opened at $150.00 on Friday. The stock's 50 day moving average price is $161.00 and its two-hundred day moving average price is $161.54. The firm has a market capitalization of $66.78 billion, a P/E ratio of 26.93, a price-to-earnings-growth ratio of 2.51 and a beta of 0.91. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same period in the prior year, the business posted $1.38 earnings per share. Zoetis's revenue for the quarter was up 1.4% on a year-over-year basis. On average, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.33%. Zoetis's dividend payout ratio is currently 35.91%.

Analyst Ratings Changes

A number of research analysts recently commented on ZTS shares. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $180.00 to $155.00 in a research note on Thursday. UBS Group cut their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Piper Sandler increased their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Finally, Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $204.63.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.